Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts

BASKING RIDGE, N.J., June 17 /PRNewswire/ — Regado Biosciences,
a privately held company leading the development of antithrombotic
aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO,
will be presenting at the 2010 Wells Fargo Healthcare Conference at
the InterContinental Hotel in Boston,
Massachusetts. Dr. Mazzo’s presentation will be given at
8:00 am (EDT) on Thursday, June 24 in the Robinson Room and
will include an overview of the Company’s pipeline with emphasis on
the lead development program, the innovative anticoagulant system,
REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology
with the creation and development of two-component drug systems.
Each system comprises a nuclease-stabilized RNA aptamer that can be
controlled directly by its specific and complementary
oligonucleotide active control agent. This technology is being
applied to injectable antithrombotics (including anticoagulants and
antiplatelet agents) in the acute and sub-acute care setting, a
multi-billion dollar market in need of therapeutics with improved
safety profiles and a greater degree of therapeutic control.
Regado’s technology is designed to give physicians the ability to
actively and directly control each system’s therapeutic effect
providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3

Regado’s lead program, the anticoagulant system REG1, consists
of two parenteral agents both administered by IV bolus, the first
being a potent highly selective Factor IXa inhibitor (RB006) and
the second being its complementary active control agen

‘/>”/>

SOURCE